Audit: QRS - Meditation for Health & Longevity

Audit conducted on 09/09/2026 05:19 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every span traced to the ER: protocol values to Therapeutic Protocol (lines 369, 375, 381), time-to-effect to Practical Considerations (line 422) and Expected Benefits (lines 153, 165), benefit/risk tiers to the ER headings, all 10 markers and 5 qualitative items to the ER Monitoring Protocol & Defining Success table (lines 454–473).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	ER’s “No established target” for rMSSD (line 462) is carried verbatim into marker_7_target; the Speculative tier is preserved for telomere length, brain aging and treatment displacement.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Conditional contraindications keep their conditions: the psychosis item retains “intensive formats: over 4 hours daily, or any silent retreat” and the PTSD item retains “trauma-sensitive formats with a trained teacher only; never unsupervised silent practice”, matching ER lines 341 and 345.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from “Populations who should avoid Meditation” (ER 339–345); Key Interactions only from the eight interaction bullets (ER 323–337); no Benefit- or Risk-Modifying Factor is surfaced in a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers or citations anywhere in the QRS. The only named parties — “Kabat-Zinn, University of Massachusetts” (action_1_label) — appear in the ER Therapeutic Protocol bullet label at line 369. Drug names in the interaction gate all appear in ER lines 323–337.
1.6	The QRS does not introduce new attributions.	🟢	No attribution beyond the ER-sourced Kabat-Zinn/UMass protocol label.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The ER’s measured, comparator-aware skepticism carries through — e.g. time_3_sub “against an established sleep treatment it is indistinguishable from zero” mirrors ER line 165.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Concrete doses, targets and cadences give the reader something to act on while the evidence framing stays objective.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	All content is stated as noun phrases and findings; no prescriptions are issued.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring targets and cadence are presented as the ER’s measurement scheme, not as instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommend”, “should”, “advise” or equivalent.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns and no imperatives anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms used (rMSSD, HbA1c, DHEA-S) are biomarker names required by the Monitoring table; prose elsewhere is plain.
2.8	Information is presented in a concise and very compact manner	🟢	Every ER bullet is reduced to a phrase; the ER’s magnitude paragraphs are dropped entirely.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by source scan — no “you”, “your”, “yours”, “yourself”.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range biomarker targets, an eight-item interaction gate and a five-item contraindication gate address exactly this reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	The headline protocol is the full 8-week / 2.5-hour-class / 45-minute-daily course rather than a minimal app habit.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward casual practice; the minimum effective dose is framed as a floor, not the recommendation.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the active-comparator shrinkage and the non-trivial harm rate, which is the distinction that matters to a risk-aware reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the page title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Hypoglycemia”, “antihypertensive medication”, “sedatives and hypnotics”, “depersonalization” are used in preference to consumer equivalents.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fourteen fixed strings match the template byte-for-byte (QRS lines 446, 493, 543, 645, 671, 829, 571, 595, 675–677 and the four tier labels in both tiered cards).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#_* and qualitative_item_# rows are expanded to marker_1–marker_10 and qualitative_item_1–5 as the template intends.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template shows changes only inside variable spans and in the repeated marker/qualitative rows; the website="evidence_review", website="audit" and website="full_review" spans, the CSS block and the footer disclaimer are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty — all four benefit tiers, all four risk tiers, the contraindication list, the interaction list, the protocol and the monitoring table are populated in the ER.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard course (Kabat-Zinn, University of Massachusetts)”, “Minimum effective dose” and “Single session or split sessions” are verbatim from ER lines 369, 375, 381; all eight interaction labels are verbatim from ER lines 323–337 apart from the plain-language glosses trimmed under 9.5.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names are verbatim from the ER table’s Biomarker column; tier labels are template-fixed; the time-to-effect labels are the outcome names the ER itself uses, as the ER has no bold label for those cells.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Source scan finds no emoji code points; the ER’s ⚠️ “Conflicted” markers on Cognitive Performance, Smoking Cessation and Reduced Memory Reliability were correctly dropped rather than carried over.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each section is condensed rather than extended: 12 ER protocol bullets reduced to 3 action cells, every magnitude paragraph dropped, each interaction bullet reduced to a single key-fact clause, and the monitoring “Why” cells kept to one clause each.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The comment opens at line 2, immediately after <!doctype html> on line 1, and closes at line 14 before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding “QRS — Metadata (invisible, parsed by audit tooling)” text sits before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It is inside an HTML comment and no metadata value is repeated in the rendered header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, and it must be because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: meditation_2026-0909-0251_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0909-0446 — correct YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: meditation_2026-0909-0251_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including git_user: evipedia-1 and git_issue: 5943; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Meditation for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Meditation for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/09/2026”, the MM/DD/YYYY form of qrs_creation_date: 2026-0909-0446.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the qrs_creator_ai_fullname frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header holds only the title and the template’s own subline; the ER’s long “Also known as” list was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All four sentences derive from the ER Conclusion (lines 495–499) and carry the three decision-relevant points: what works, how much it shrinks under active comparison, and that harms are not rare.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“trainable attention skill, not a treatment” ← line 495; the four consistent effects and “real but modest … shrink against another active practice” ← line 495; “claims that reach furthest rest on the weakest footing” ← line 497; “Harms are neither rare nor, for most people, severe” ← line 499.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “low mood”, “self-reported sleep”, “calmer blood pressure” and “long-standing pain” are used in place of clinical register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, author, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	Magnitude is expressed qualitatively as “real but modest”; no numeric result appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items come from the “Populations who should avoid Meditation” list at ER lines 339–345, which sits inside that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are present and none is invented: active psychosis/schizophrenia-spectrum, mania/unstabilized bipolar I, acute suicidal crisis, depersonalization-derealization disorder, untreated PTSD with active flashbacks.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Five discrete <li> elements inside the stop_items span at QRS lines 573–591.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The mechanistic rationale on the depersonalization item (“for which sustained attention to internal body sensation is symptom-provoking”, ER line 344) is stripped, and no item carries a trailing dash clause; what remains on items 1, 3 and 5 is applicability scope preserved under 8.5, not explanation.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“symptoms in the past 12 months” and “(over 4 hours daily, or any silent retreat)” are retained on item 1; “active ideation with plan or intent, until stabilized under clinical care” on item 3; the supervised-format restriction on item 5 — each is the qualifier that decides whether the gate applies.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses anywhere in Key Interactions & Contraindications; its parentheticals are plain drug and threshold lists.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does name five such populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no absence comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map one-to-one onto the eight interaction bullets at ER lines 323–337.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight interaction bullets are present, and none of the five contraindication populations is duplicated into this gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight discrete <li> elements inside the caution_items span at QRS lines 597–636.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Severity:”, “Consequence:” and “Mitigation:” clause from the ER bullets is stripped, leaving one key-fact clause each; the ER’s em-dash glosses “— drugs that raise serotonin signaling” (line 325) and “, which push the pancreas to release insulin” (line 327) are removed.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All eight ER example-drug lists survive intact — amlodipine/lisinopril/losartan/hydrochlorothiazide, escitalopram/sertraline, insulin/glipizide, zolpidem/lorazepam/diazepam, diphenhydramine/doxylamine/melatonin, ashwagandha/L-Theanine/magnesium glycinate/valerian, beetroot nitrate/garlic extract/potassium, and the four stacking interventions.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation appears inside any parenthetical in the ER’s interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight such interactions, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no absence comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action cells trace to the ER Therapeutic Protocol bullets at lines 369, 375 and 381.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The canonical tested course, the minimum effective dose and the session-structure options are the three bullets that determine what a reader would actually do; the remaining bullets are variants, moderators or non-actionable notes.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains twelve bullets, so all three sets are used and none needed hiding.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “8 weekly 2.5-hour classes” (ER 369), “13 minutes daily” (ER 375), “20–45 min, or 2 × 10–20 min” (ER 381), with subs carrying the silent day / home practice, the eight-versus-four-week result, and the total-minutes finding.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Anxiety and depressive symptoms, blood pressure and heart rate, and sleep quality — drawn from ER line 422 (“Acute drops in heart rate and blood pressure occur within a single session. Mood, attention and sleep changes emerged at eight weeks but not at four”).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The order matches the ER’s own High-tier benefit ordering: Reduced Anxiety and Depressive Symptoms (line 151), Lower Blood Pressure (line 157), Improved Sleep Quality (line 163).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated: “8 weeks”, “Single session” and “6–8 weeks” with subs from ER lines 153, 379 and 165 respectively.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information (dedicated bullet at line 422), so the row is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen items are the ER’s own benefit headings from lines 149–229.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 545–564, each mapped to the matching ER tier.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Every ER “Magnitude:” paragraph and narrative body is dropped; only the heading text survives, semicolon-separated.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit tier; the ER’s effect sizes (0.38, 0.30, 5.1–5.6 mmHg, RR 0.77) are all absent.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items (4 high, 5 medium, 2 low, 2 speculative), so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items are the ER’s own risk headings from lines 251–303.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 647–665, each mapped to the matching ER tier.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the ER heading text survives; the prevalence figures (8.3%, 58%, 37%, 11%, 28 cases) and mechanistic paragraphs are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk tier.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items (1 high, 2 medium, 4 low, 1 speculative), so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at lines 454–465, in the same order.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER rows present with targets intact: seated blood pressure 110–120 / 70–78 mmHg, resting heart rate 50–65 bpm, hs-CRP below 1.0 mg/L, HbA1c 5.0–5.4%, morning cortisol 10–18 µg/dL at 08:00, DHEA-S upper half of range, rMSSD no established target, PSQI 5 or below, PSS 13 or below, anxiety/depression questionnaires 4 or below.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 820–823 reproduce the ER cadence sentence at line 452: questionnaires at 4 and 8 weeks, blood pressure and resting heart rate every two weeks through the first 8 weeks, blood markers at 6 months and every 6–12 months thereafter.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the “Subjective markers tracked alongside the laboratory values” list at ER lines 469–473.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five are present: sleep onset latency and night wakings, daytime energy and afternoon crash severity, cognitive clarity, reactivity, and the adverse-marker triad of detachment, intrusive memories and unusual over-alertness.

Issues 09/09/2026 05:19

Pass rate 100.00%. No issues found.

Issues 09/09/2026 05:11

1. 4.2 / 4.3 — Protocol label abbreviated: [action_1_label] at line 450 reads “Standard course”, but the ER bold label at ER line 369 is “Standard course (Kabat-Zinn, University of Massachusetts)”; the label must be verbatim and unabbreviated, as the eight [caution_items] labels correctly are.

Fixes 09/09/2026 05:11

1. 4.2 / 4.3 — Protocol label made verbatim: [action_1_label] changed from “Standard course” to “Standard course (Kabat-Zinn, University of Massachusetts)”, matching the ER bold label verbatim.

Issues 09/09/2026 05:05

1. 1.3 — Contraindication broadened beyond ER: The first [stop_items] entry (line 573) states “Active psychosis, or schizophrenia-spectrum symptoms in the past 12 months”, whereas ER line 341 requires “a schizophrenia-spectrum diagnosis with symptoms in the past 12 months” — dropping the diagnosis requirement strengthens the gate to cover anyone with recent symptoms.

Fixes 09/09/2026 05:05

1. 1.3 — Contraindication broadened beyond ER: Restored the ER’s diagnosis requirement in the first [stop_items] entry, changing “Active psychosis, or schizophrenia-spectrum symptoms in the past 12 months” to “Active psychosis, or a schizophrenia-spectrum diagnosis with symptoms in the past 12 months”.

Issues 09/09/2026 04:58

1. 4.5 — Sheet overflows one A4 page: The rendered content runs to roughly two A4 pages: the Key Interactions gate (lines 598–637) alone occupies about twenty wrapped lines, and every Protocol and Time-to-Effect sub-cell (lines 456–458, 470–473, 484–486, 504–507, 518–521, 532–534) runs four wrapped lines. ER content was transcribed rather than condensed to the per-section budget.
2. 11.2 — Time to Effect not ordered by magnitude: Sleep quality is placed second and blood pressure third, but the ER’s High benefit tier ranks Lower Blood Pressure above Improved Sleep Quality (ER lines 157 and 163), the order the QRS Benefits card itself uses at line 547.
3. 1.3 — Sleep follow-up claim strengthened: [time_2_sub] at line 519 states sleep quality “grows at follow-up” unconditionally, whereas the ER (line 165) confines that growth to attention-matched controls and reports zero benefit against an established sleep treatment.
4. 9.4 — Mechanistic rationale left in interaction items: The calming-supplements item (line 625) leads with “Act on the same endpoints and” before the key fact, and the glucose-lowering (line 611) and OTC-sedating (line 620) items chain two clauses where one key fact suffices.

Fixes 09/09/2026 04:58

1. 4.5 — Sheet condensed toward one page: Trimmed the three Protocol sub-cells, both surviving Time-to-Effect sub-cells, two Contraindication parentheticals and two Qualitative items, removing roughly 60 words of transcribed ER prose while keeping every mandated qualifier.
2. 11.2 — Time to Effect reordered by magnitude: Swapped the second and third cells so the order is anxiety/depressive symptoms, blood pressure and heart rate, sleep quality — matching the ER’s High benefit tier and the QRS Benefits card.
3. 1.3 — Sleep follow-up claim requalified: Replaced “improves … and grows at follow-up” with “Improves in adults with existing sleep disturbance; against an established sleep treatment it is indistinguishable from zero,” restoring the ER’s comparator condition.
4. 9.4 — Mechanistic rationale stripped from interactions: Calming supplements reduced to “Can mask whether practice is working”, glucose-lowering agents to “Hypoglycemia more likely on fixed doses”, OTC sedating agents to “Additive drowsiness”, and sedatives/hypnotics to “Marked drowsiness during sessions”.

Issues 09/09/2026 04:51

1. 7.2 — At-A-Glance exceeds word limit: The [at_a_glance] paragraph (lines 434–438) runs to 64 words against the 60-word ceiling.

Fixes 09/09/2026 04:51

1. 7.2 — At-A-Glance trimmed to word limit: Condensed [at_a_glance] from 64 to 58 words (“rather than a treatment that is taken” → “not a treatment”; “shrink when compared against” → “shrink against”), keeping every fact and its ER support intact.